Author’s response to reviews

Title: ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY (ALLIANCE) TRIAL A021501: PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE Pancreas

Authors:

Matthew Katz (mhgkatz@mdanderson.org)
Fang-Shu Ou (ou.fang-shu@mayo.edu)
Joseph Herman (jmherman@mdanderson.org)
Syed Ahmad (ahmadsy@ucmail.uc.edu)
Brian Wolpin (Brian_Wolpin@dfci.harvard.edu)
Robert Marsh (rmarsh@northshore.org)
Qian Shi (Shi.qian2@mayo.edu)
Michael Chuong (MichaelChu@baptisthealth.net)
Lawrence Schwarz (lhs2120@cumc.columbia.edu)
Wendy Frankel (Wendy.Frankel@osumc.edu)
Eric Collisson (Eric.Collisson@ucsf.edu)
Eugene Koay (EKOay@mdanderson.org)
JoLeen Hubbard (Hubbard.joleen@mayo.edu)
James Leenstra (Leenstra.james@mayo.edu)
Jeffrey Meyerhardt (Jeffrey_meyerhardt@dfci.harvard.edu)
Eileen O'Reilly (Oreillye@mskcc.org)

Version: 1 Date: 10 Apr 2017
Author’s response to reviews:

RE: BCAN-D-17-00255: ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY (ALLIANCE) TRIAL A021501: PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS

Editors:

As requested in your email dated April 6, please accept the following responses to queries:

1) Ethical and funding approvals have been forwarded to BMCSeriesEditorial@biomedcentral.com. The trial was approved for national activation by the NCI/CTEP with reference number PA021501_R02PAPP02.

2) Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA031983, U10CA032291, U10CA180858, and U10CA180867. Also supported in part by funds from the National Pancreas Foundation and the Sky Foundation. No funding agency had involvement in the design of the study, or the collection, analysis and interpretation of data. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

3) The study is open for enrollment nationally. Eleven patients have been enrolled since it was activated in December, 2016.
4) No related articles have been submitted to other journals.

Thank you,

Matthew Katz